Physician profile
Heather Brunk
NPI 1922697168
$2,870.84
in general payments reported to CMS, 2019-2025
36 companies · $544 in 2025
The $544 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $507 · 2023: $1,001 · 2024: $229 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.23 |
| Education | $274.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.25 | 2021-2025 | |
| Novo Nordisk INC | $300.19 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $233.31 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $226.55 | 2024-2025 | Vyloy |
| Biohaven Pharmaceutical Holding Company Ltd. | $163.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.41 | 2021-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Lilly USA, LLC | $141.75 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $139.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.56 | 2025 | Opdivo |
| Axsome Therapeutics, INC. | $92.52 | 2022-2023 | Auvelity |
| Pfizer INC. | $89.21 | 2023 | |
| Exact Sciences Corporation | $81.20 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $64.36 | 2021-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.04 | 2021 | |
| Lundbeck LLC | $57.50 | 2023 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $44.49 | 2021 | |
| Glaxosmithkline, LLC. | $43.54 | 2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $39.68 | 2023 | Austedo, Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $33.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.76 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.10 | 2023 | Evkeeza |
| Ipsen Biopharmaceuticals, INC | $27.10 | 2025 | Onivyde |
| Medtronic, INC. | $24.86 | 2023 | Guardian Connect |
| Alkermes, INC. | $24.32 | 2021 | |
| Merck Sharp & Dohme LLC | $22.62 | 2025 | Keytruda, Welireg |
| Beigene USA, INC. | $21.25 | 2025 | Tevimbra |
| Sanofi Pasteur INC. | $20.49 | 2023 | |
| Indivior INC. | $20.40 | 2023 | Sublocade |
| Menarini Silicon Biosystems, INC. | $19.24 | 2025 | |
| Sobi, INC | $18.84 | 2024 | |
| Rigel Pharmaceuticals, INC. | $16.24 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Daiichi Sankyo INC. | $16.14 | 2025 | Datroway |
| Alexion Pharmaceuticals, INC. | $16.11 | 2025 | Ultomiris |
| Amgen INC. | $15.78 | 2023 | Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $14.78 | 2023 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $14.36 | 2023 | Epclusa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Brunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.